Drug news
FDA approves Fabior (Allergan) for Acne vulgaris in 12 year olds and upwards
The FDA has approved the New Drug Application for Fabior (tazarotene) Foam, 0.1%, from Allergan, for the treatment of Acne vulgaris in patients 12 years of age and older. It is the only retinoid in a topical foam formulation approved for this indication in the US. The approval of tazarotene foam was based on two multi-centre, randomized, double-blind, vehicle-controlled pivotal Phase III studies conducted in the US and Canada.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins